FDA warns 350 practices against unapproved versions of Botox

12/28/2012 | Medical News Today

The FDA warned more than 350 medical practices regarding unapproved versions of wrinkle fighter Botox as well as other drugs from Canada Drugs and its subsidiaries. The products could be unsafe, ineffective, counterfeit and contaminated, the FDA said. The FDA asked the practices to stop using the treatments in patients.

View Full Article in:

Medical News Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL